Hepatitis A and B Combined Vaccine (HABV)

Revision Date: January 23, 2017

Please consult the Product Monograph ¹ for further information about the vaccine.	
	TWINRIX® Junior & TWINRIX®
Manufacturer	GlaxoSmithKline Inc.
Licensed use	Twinrix® Junior – individuals one year up to and including 18 years of age Twinrix® - Individuals 19 years of age and older
Off-license use	None
Indications for use of provincially funded vaccine	Pre-exposure: Individuals one year of age and older (who are eligible for both hepatitis A and hepatitis B vaccines) including those with: ➤ Hemophilia A or B receiving plasma-derived replacement clotting factors. ➤ Chronic liver disease, including individuals infected with hepatitis C. ➤ Lifestyle risks of infections including people engaging in illicit drugs (injectable and non-injectable) and men having sex with men. Notes: • Twinrix® Junior/Twinrix® should not be used for individuals who require double-strength hepatitis B vaccine. See Biological Products – Hepatitis B Vaccine. • Pre-immunization serology for anti-HAV (IgG) is recommended for some individuals. See Biological Products - Hepatitis A Vaccine. Post-exposure: Twinrix® and Twinrix® Junior is not recommended for hepatitis A or hepatitis B post-exposure prophylaxis.
Dose	Twinrix® Junior (one year up to and including 18 years of age) ❖ 0.5 mL dose Twinrix® (19 years of age and older) ❖ 1.0 mL
Route	Intramuscular injection
Schedule	 Dose 1 – day 0 Dose 2 – one month after dose 1 Dose 3 – six months after dose 1



Contraindications	 Known severe hypersensitivity to any component of Twinrix® Junior/Twinrix® Anaphylactic or other allergic reactions to a previous dose of vaccine containing hepatitis A or hepatitis B antigens.
Precautions	It is possible that individuals may be in the incubation period of a hepatitis A or hepatitis B infection at the time of immunization. It is not known whether Twinrix® Junior/Twinrix® will prevent hepatitis A and hepatitis B in such cases.
Possible reactions	See Product Monograph
Pregnancy	Twinrix® may be administered to pregnant women who meet the indications for use of provincially funded vaccine. ^{1,2} The safety of TWINRIX® has not been studied in clinical trials but there is no theoretical reason to suspect an increased risk of adverse events to the mother or infant. ²
Lactation	TWINRIX® may be administered to breastfeeding mothers who meet the indications for use of provincially funded vaccine. ²
Program Notes	 1997 January 1 – Introduced into program 2014 January 10 – For eligible adults requiring both hepatitis A and B vaccines

References

¹ GlaxoSmithKline Inc. (2016, August 11). Twinrix®: Combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine. *Product Monograph*.

² National Advisory Committee on Immunization. (2017). *Canadian Immunization Guide* (Evergreen ed.). Ottawa, ON: Public Health Agency of Canada. www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php